Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report

Rogerio Serafim Parra, Marley Ribeiro Feitosa, Vanessa Foresto Machado, Leandra Naira Zambelli Ramalho, Jose Joaquim Ribeiro da Rocha and Omar Feres

Abstract

Introduction: Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety. Complications of this treatment are related to immunosuppression and include higher risk of serious infections and malignant neoplasia. Although extremely rare, fulminant liver damage related to infliximab therapy has been reported.

Case presentation: We present the case of a 38-year-old Afro-Brazilian woman with refractory ulcerative colitis who was started on infliximab. She had no previous history of liver disease, alcohol abuse, or infection. After the fifth dose of the medication, drug-induced liver injury was diagnosed. Treatment was discontinued but our patient’s condition was aggravated by severe cholestasis and grade III/IV encephalopathy, requiring liver transplantation.

Conclusion: Drug-induced liver injury is an uncommon complication of infliximab. Current consensus recommends screening for liver dysfunction prior to and during therapy. This case emphasizes the need for vigilance and highlights a rare and potentially lethal complication.

Keywords: Hepatitis, Infliximab, Liver failure, Liver transplantation, Ulcerative colitis
resonance scan demonstrated acute liver damage. She developed grade III encephalopathy with marked confusion and incomprehensible speech and had an emergency whole liver transplantation. The surgery was successful. A histopathological analysis of her explanted liver revealed extensive necrosis compatible with fulminant hepatic failure (Fig. 1). After the procedure, results from hepatic tests normalized (Fig. 2). Our patient made a full recovery and is receiving immunosuppressive therapy with tacrolimus. No signs of liver rejection or colitis reactivation have yet been noted.

Discussion
The number of patients treated with IFX has rapidly increased worldwide. An estimated 2 million people were exposed to this drug from 1998 to 2014. The colectomy rate in UC significantly decreased after the introduction of this class of drugs [12–15]. Despite this notable success, physicians must be aware of the possible complications, especially those related to immunosuppression such as serious infections and malignant neoplasia.

Elevated liver enzymes (especially ALT) have been reported during IFX treatment but are usually transitory and have no clinical implications. Fulminant liver failure is an extremely rare and serious event that requires a liver transplant, with high morbidity and mortality [16–18]. IFX-induced acute liver failure may be explained in three possible ways: autoimmune hepatitis, cholestatic injury, and direct toxicity [19].

In the present case, our patient had no history of alcohol consumption or concomitant use of any hepatotoxic drugs. Serological tests for infectious hepatitis, HIV, or other viruses were negative. Autoimmune disease was also excluded. Histopathological analysis of the explanted liver evidenced diffuse hepatitis intertwined with areas of necrosis, suggesting direct liver damage. A diagnosis of IFX-induced hepatitis was made considering the temporal relationship with IFX exposure, lack of other possible causes of liver injury, laboratory changes, and clinical deterioration.

Current guidelines support screening for liver dysfunction at 4-month intervals. It is also important to rule out any hepatotoxic risk factor prior to IFX therapy. Discontinuation of IFX is recommended if transaminase levels reach three times the upper normal limits, especially if associated with clinical manifestations [20].

Conclusion
This report calls attention to a rare and potentially lethal adverse effect of IFX. All efforts should be made to rule out any pre-existing liver disease before initiating IFX therapy and vigilance must continue during the maintenance treatment, which must be interrupted if aminotransferases elevate more than three times above the normal levels. Signs of abrupt clinical deterioration should raise suspicion for fulminant liver disease.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Fig. 1 Hepatic necrosis. Hematoxylin and eosin staining, original magnification 10x
Abbreviations
AST: aspartate aminotransferase; ALT: alanine aminotransferase; HIV: human immunodeficiency virus; IFX: infliximab; INR: international normalized ratio; UC: ulcerative colitis.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RSP interpreted the patient data and was a major contributor to writing the manuscript. MRF and VFM collected and helped interpret patient data, and contributed to writing the manuscript. LNZR analyzed histopathological findings. JJRR and OF designed, reviewed, and approved the final version of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors have no disclosures to make and have had no source of funding in the preparation of this manuscript. We would like to thank Prof. Ênio David Mente for his technical support.

Author details
1Division of Coloproctology, Department of Surgery and Anatomy, Medical School of Ribeirão Preto, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP Zip: 14048-900, Brazil. 2Department of Pathology, Medical School of Ribeirão Preto, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP Zip: 14048-900, Brazil.

Received: 6 February 2015 Accepted: 8 October 2015
Published online: 30 October 2015

References
1. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24 Suppl 1:13-14.
2. Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014;43(3):457–78.
3. Seo GS, Chae SC. Biological therapy for ulcerative colitis: an update. World J Gastroenterol. 2014;20(3):13234–8.
4. Björnsson E, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13(3):602–8.
5. Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26(4):578–81.
6. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc. 2001;76(4):578–81.
7. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5(3):193–200.
8. Ierardi E, Valle ND, Nacchiero MC, De Francesco V, Stoppino G, Panella C. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig. 2006;26:673.
9. Cheng FK, Bridges EE, Betenridge JD. Drug-induced liver injury from initial dose of infliximab. Mil Med. 2015;180(8):e723–4.
10. Moum B, Konopski Z, Tufteland KF, Jahnsen J. Occurrence of hepatotoxicity and elevated liver enzymes in a Crohn’s disease patient treated with infliximab. Inflamm Bowel Dis. 2007;13:1584.

11. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–64.

12. Sandborn WJ, Rutgeertps P, Feagan BG, Reinsch W, Olson A, Johannes J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–60.

13. Colombel JF, Rutgeertps P, Reinsch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–201.

14. Arias MT, Vandé Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(3):531–8.

15. Gustavsson A, Jämerot G, Hentervig E, Fris-Liby I, Blomquist L, Karlén P, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther. 2010;32(8):984–9.

16. Rowe BW, Gala-Lopez B, Tomlinson C, Grgis S, Shapiro JA. Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: a cautionary tale times two. Transpl Int. 2013;26(12):e110–2.

17. Kinnunen U, Färkkilä M, Mäkisalo H. A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. J Crohns Colitis. 2012;6(6):724–7.

18. Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis. 2010;28(3):508–18.

19. Carvalheiro J, Mendes S, Sofia C. Infliximab induced liver injury in Crohn’s disease: a challenging diagnosis. J Crohns Colitis. 2014;8(5):436–7.

20. Miehsler W, Novacek G, Wend H, Vogelsang H, Knoblach P, Kaser A, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4(3):221–56.